Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 14, 2011


Title: Small Interfering RNAs Targeting Feline Herpes Virus

Patent Number: 7,977,321

Filed: Feb. 12, 2009

Lead Inventor: Stephen Kania, University of Tennessee

The patent, its abstract states, claims “polynucleotides, compositions thereof, and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 in vivo and/or in vitro.”

Title: siRNA Targeting TNF-Alpha

Patent Number: 7,977,471

Filed: Sept. 12, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF-alpha.”

Title: RNA Interference-Mediated Inhibition of Myostatin Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,977,472

Filed: April 22, 2010

Lead Inventor: Leonid Beigelman, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating myostatin gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference using small nucleic acid molecules.”

Title: Compositions and Methods Using siRNA Molecules for Treatment of Gliomas

Application Number: 20110165227

Filed: March 16, 2011

Lead Inventor: Hai Yan, Duke University (Sirnaomics)

The invention, the patent application's abstract states, “provides small interfering RNA molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas.”

Title: Methods for Producing Inducible and/or Repressible Expression Active Linear RNA Interference Cassettes and Inducible and/o Repressible Expression Active Linear Gene Cassettes and Their Uses

Application Number: 20110166042

Filed: May 25, 2009

Inventor: Khalid Khabar, King Faisal Specialist Hospital & Research Centre

The invention, the patent application's abstract states, relates to a “method for producing inducible and/or repressible expression active linear RNA interference constructs.” The method involves PCR amplification of a source polynucleotide comprised of an inhibitory RNA coding sequence of interest or of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest.

The invention also relates to a method for producing inducible and/or repressible expression active linear gene constructs involving PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or PCR amplification using the DNA sequence as a template, the abstract adds.

Title: RNA Compositions for Modulating Immune Response

Application Number: 20110166198

Filed: April 8, 2009

Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

“This invention features modified iRNA agents that modulate an immune response, methods of making and identifying iRNA agents that modulate an immune response, and methods of using the iRNA agents to modulate an immune response,” the patent application's abstract states.

Title: RNAi Compound Targeted to Thrombospondin-1 and Applications Thereof

Application Number: 20110166199

Filed: Jan. 6, 2011

Lead Inventor: Ming-Derg Lai, National Cheng Kung University

The invention, the patent application's abstract states, “relates to an RNAi compound and an expression plasmid for inhibiting expression of thrombospondin-1, which comprises a target sequence selected from [the] thrombospondin-1 gene. The ... invention also relates to a pharmaceutical composition comprising the RNAi compound and applications thereof.

“The RNAi compound can reduce the expression of thrombospondin-1 to activate immune responses,” it adds. “In addition, the ... invention also discloses that an RNAi compound targeted to thrombospondin-1 gene can delay tumor progression.”

Title: Methods of Using miR-210 as a Biomarker for Hypoxia and as a Therapeutic Agent for Treating Cancer

Application Number: 20110166200

Filed: April 16, 2009

Lead Inventor: Zhan Zhang, Merck

The invention “provides compositions and methods for predicting the hypoxia response in tumor cells, methods for predicting the likelihood of cancer metastasis, and methods for inhibiting tumor cell proliferation using a microRNA comprising miR-210,” the patent application's abstract states.

Title: miRNAs as Therapeutic Targets in Cancer

Application Number: 20110166201

Filed: June 5, 2009

Lead Inventor: Jingfang Ju, Stony Brook University Medical Center

“The invention relates to the application of miR-192 and miR-215,” the patent application's abstract states. “Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase and thymidylate synthase. Particularly, up-regulation of these miRNAs reduces cellular proliferation. ... Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.